A novel prognostic signature for lung adenocarcinoma based on cuproptosis-related lncRNAs: A Review. Issue 49 (9th December 2022)

• Record Type: Journal Article
• Authors: Di, Huang; Zhao, Jiting; Zhu, Xue; Zhou, Xinpeng; Hu, Yuanlong; Wang, Mengjie; Qiu, Zhanjun; Zhang, Wei; Chen, Xianhai
• Is Part Of: Medicine. Volume 101:Issue 49(2022)
• Page Start: e31924
• Publication Date: 2022-12-09
• Subjects: cuproptosis -- cuproptosis-related lncRNAs (CRlncRNAs) -- lung adenocarcinoma (LUAD) -- TCGA; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000031924
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Lung adenocarcinoma (LUAD) is a highly heterogeneous disease with complex pathogenesis, high mortality, and poor prognosis. Cuproptosis is a new type of programmed cell death triggered by copper accumulation that may play an important role in cancer. LncRNAs are becoming valuable prognostic factors in cancer patients. The effect of cuproptosis-related lncRNAs (CRlncRNAs) on LUAD has not been clarified. Based on the Cancer Genome Atlas database, CRlncRNAs were screened by co-expression analysis of cuproptosis- related genes and lncRNAs. Using CRlncRNAs, Cox and LASSO regression analyses constructed a risk prognostic model. The predictive efficacy of the model was assessed and validated using survival analysis, receiver operating characteristic curve, univariate and multifactor Cox regression analysis, and principal component analysis. A nomogram was constructed and calibration curves were applied to enhance the predictive efficacy of the model. Tumor Mutational Burden analysis and chemotherapeutic drug sensitivity prediction were performed to assess the clinical feasibility of the risk model. The novel prognostic signature consisted of 5 potentially high-risk CRlncRNAs, MAP3K20-AS1, CRIM1-DT, AC006213.3, AC008035.1, and NR2F2-AS1, and 5 potentially protective CRlncRNAs, AC090948.1, AL356481.1, AC011477.2, AL031600.2, and AC026355.2, which had accurate and robust predictive power for LUAD patients. Collectively, the novel prognostic signature constructed based on CRlncRNAs can effectively assess and predict the prognosis of patients and provide a new perspective for the diagnosis and treatment of LUAD.